WO2009158431A3 - Composés et compositions en tant qu’inhibiteurs de kinase - Google Patents

Composés et compositions en tant qu’inhibiteurs de kinase Download PDF

Info

Publication number
WO2009158431A3
WO2009158431A3 PCT/US2009/048509 US2009048509W WO2009158431A3 WO 2009158431 A3 WO2009158431 A3 WO 2009158431A3 US 2009048509 W US2009048509 W US 2009048509W WO 2009158431 A3 WO2009158431 A3 WO 2009158431A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidine derivatives
kinase inhibitors
analplastic
igf
alk
Prior art date
Application number
PCT/US2009/048509
Other languages
English (en)
Other versions
WO2009158431A2 (fr
Inventor
Thomas H. Marsilje, Iii
Wenshuo Lu
Bei Chen
Xiaohui He
Songchun Jiang
Kunyong Yang
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Priority to MX2010014568A priority Critical patent/MX2010014568A/es
Priority to US13/000,999 priority patent/US8445505B2/en
Priority to CA2729546A priority patent/CA2729546A1/fr
Priority to AU2009262198A priority patent/AU2009262198B2/en
Priority to EA201100078A priority patent/EA201100078A1/ru
Priority to EP09770964A priority patent/EP2331526A2/fr
Priority to JP2011516619A priority patent/JP2011526291A/ja
Priority to CN200980129584XA priority patent/CN102203083A/zh
Publication of WO2009158431A2 publication Critical patent/WO2009158431A2/fr
Publication of WO2009158431A3 publication Critical patent/WO2009158431A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La présente invention concerne de nouveaux dérivés de pyrimidine et des compositions pharmaceutiques de ceux-ci, ainsi que des procédés d’utilisation de ces composés. Par exemple, les dérivés de pyrimidine de l’invention peuvent être utilisés pour traiter, améliorer ou prévenir une pathologie sensible à l’inhibition du facteur de croissance insulinomimétique (IGF-1R) ou de la kinase du lymphome anaplasique (ALK).
PCT/US2009/048509 2008-06-25 2009-06-24 Composés et compositions en tant qu’inhibiteurs de kinase WO2009158431A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2010014568A MX2010014568A (es) 2008-06-25 2009-06-24 Derivados de pirmidina como inhibidores de cinasa.
US13/000,999 US8445505B2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
CA2729546A CA2729546A1 (fr) 2008-06-25 2009-06-24 Composes et compositions en tant qu'inhibiteurs de kinase
AU2009262198A AU2009262198B2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
EA201100078A EA201100078A1 (ru) 2008-06-25 2009-06-24 Производные пиримидина в качестве ингибиторов киназы
EP09770964A EP2331526A2 (fr) 2008-06-25 2009-06-24 Dérivés de la pyrimidine comme inhibiteurs de kinases
JP2011516619A JP2011526291A (ja) 2008-06-25 2009-06-24 キナーゼ阻害剤としてのピリミジン誘導体
CN200980129584XA CN102203083A (zh) 2008-06-25 2009-06-24 作为激酶抑制剂的嘧啶衍生物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
US61/075,583 2008-06-25

Publications (2)

Publication Number Publication Date
WO2009158431A2 WO2009158431A2 (fr) 2009-12-30
WO2009158431A3 true WO2009158431A3 (fr) 2010-03-11

Family

ID=41076758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048509 WO2009158431A2 (fr) 2008-06-25 2009-06-24 Composés et compositions en tant qu’inhibiteurs de kinase

Country Status (11)

Country Link
EP (1) EP2331526A2 (fr)
JP (1) JP2011526291A (fr)
KR (1) KR20110020940A (fr)
CN (1) CN102203083A (fr)
AU (1) AU2009262198B2 (fr)
BR (1) BRPI0914545A2 (fr)
CA (1) CA2729546A1 (fr)
EA (1) EA201100078A1 (fr)
MX (1) MX2010014568A (fr)
UA (1) UA101057C2 (fr)
WO (1) WO2009158431A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
JP2013522215A (ja) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー 組合わせ抗癌療法
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP3121173A1 (fr) * 2011-11-29 2017-01-25 F. Hoffmann-La Roche AG Dérivés d'aminopyrimidine comme modulateurs lrrk2
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
US10202356B2 (en) * 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
AU2015266453C1 (en) * 2014-05-30 2018-09-13 Shanghai Emerald Wellcares Pharmaceutical Co., Ltd Alk kinase inhibitor, and preparation method and use thereof
CN110312711A (zh) * 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
CN107488148A (zh) * 2017-06-26 2017-12-19 安徽省黄淮兽药有限公司 一种苯丙酰胺类杀虫剂及其制备方法
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202045008A (zh) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064655A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy) pyrimidines substitues en 5, utilises comme agents antineoplasiques
WO2003026666A1 (fr) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Derives de 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine utilises comme inhibiteurs de la kinase, en particulier comme inhibiteurs de la kinase src
WO2005016893A2 (fr) * 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
WO2005026158A1 (fr) * 2003-09-16 2005-03-24 Novartis Ag Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
WO2005026130A1 (fr) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines utiles dans le traitement de troubles proliferatifs
WO2006074057A2 (fr) * 2004-12-30 2006-07-13 Exelixis, Inc. Modulateurs de kinase et procedes d'utilisation
WO2007027238A2 (fr) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Inhibiteurs de kinase jak et utilisations de ceux-ci
WO2008005538A2 (fr) * 2006-07-05 2008-01-10 Exelixis, Inc. Procédés d'utilisation de modulateurs de kinase igf1r et abl
US20080176881A1 (en) * 2006-12-08 2008-07-24 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009017838A2 (fr) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
WO2009103652A1 (fr) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulateurs de la bêta-amyloïde

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004032446D1 (de) * 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
AU2007333394C1 (en) * 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064655A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy) pyrimidines substitues en 5, utilises comme agents antineoplasiques
WO2003026666A1 (fr) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Derives de 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine utilises comme inhibiteurs de la kinase, en particulier comme inhibiteurs de la kinase src
WO2003026664A1 (fr) * 2001-09-26 2003-04-03 Bayer Corporation Derives de la 2-phenylamino-4- (5-pyrazolylamino) -pyramidine, inhibiteurs de kinases et en particulier de la kinase src
WO2005016893A2 (fr) * 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
WO2005026158A1 (fr) * 2003-09-16 2005-03-24 Novartis Ag Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
WO2005026130A1 (fr) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines utiles dans le traitement de troubles proliferatifs
WO2006074057A2 (fr) * 2004-12-30 2006-07-13 Exelixis, Inc. Modulateurs de kinase et procedes d'utilisation
WO2007027238A2 (fr) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Inhibiteurs de kinase jak et utilisations de ceux-ci
WO2008005538A2 (fr) * 2006-07-05 2008-01-10 Exelixis, Inc. Procédés d'utilisation de modulateurs de kinase igf1r et abl
US20080176881A1 (en) * 2006-12-08 2008-07-24 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009017838A2 (fr) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
WO2009103652A1 (fr) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulateurs de la bêta-amyloïde

Also Published As

Publication number Publication date
CA2729546A1 (fr) 2009-12-30
UA101057C2 (en) 2013-02-25
KR20110020940A (ko) 2011-03-03
EA201100078A1 (ru) 2011-08-30
BRPI0914545A2 (pt) 2017-05-23
AU2009262198A1 (en) 2009-12-30
MX2010014568A (es) 2011-03-29
JP2011526291A (ja) 2011-10-06
CN102203083A (zh) 2011-09-28
AU2009262198B2 (en) 2012-09-27
EP2331526A2 (fr) 2011-06-15
WO2009158431A2 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
WO2010002655A3 (fr) Composés et compositions en tant qu’inhibiteurs de kinase
WO2009032668A3 (fr) Composés et compositions en tant qu'inhibiteurs de kinase
WO2009158431A3 (fr) Composés et compositions en tant qu’inhibiteurs de kinase
WO2008073687A3 (fr) Composés et compositions inhibant la protéine kinase
UA100846C2 (uk) Сполуки та композиція як інгібітори протеїнкінази
WO2009126514A8 (fr) Composés et compositions en tant qu'inhibiteurs de kinase
WO2009126515A8 (fr) Composés et compositions comme inhibiteurs de la protéine kinase
WO2008049123A8 (fr) Compositions et procédés pour l'inhibition de la voie jak
WO2006123113A3 (fr) Composes chimiques
MY148634A (en) Pyridazinone derivatives
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
WO2009108383A3 (fr) Dérivés de xanthine substitués
WO2008046919A3 (fr) Composés hétérocycliques et leur utilisation comme inhibiteurs de la glycogène synthase kinase 3
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2009156041A3 (fr) Dérivés de thiazolyl-piperidine
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
WO2009105969A8 (fr) Analogues d'épothilone, leurs compositions pharmaceutiques, leur utilisation et leurs préparations
WO2009121535A3 (fr) Composés antiprolifératifs et leurs utilisations thérapeutiques
WO2008042282A3 (fr) Modulateurs de jak-2 et méthodes d'utilisation
WO2009094560A3 (fr) Thiénopyranones en tant qu'inhibiteurs de kinase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980129584.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770964

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/014568

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 13000999

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2729546

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011516619

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009262198

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009770964

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 432/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117001749

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201100078

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2009262198

Country of ref document: AU

Date of ref document: 20090624

Kind code of ref document: A